FDA panel discusses Merck's Vorapaxar

A panel of external FDA advisers is meeting to discuss whether to approve recommending Merck's (MRK -0.8%) Vorapaxar drug for preventing drug clots.

On Monday, the agency said in a preliminary review that the treatment should be authorized following "robustly positive" clinical trial results.

Vorapaxar, which Merck plans to sell under the brand name Zontivity, is designed to prevent heart-related deaths, heart attacks and strokes in patients who have recently suffered a heart attack but not a stroke.

You can follow updates from the meeting on Twitter here.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs